Abstract
Since fragile X syndrome (FXS) is a typical X-linked mendelian disorder, the protein product associated with the disease (FMRP) is absent or reduced not only in the affected individuals but, in case of full mutation, also in their mothers. Here, by using the mouse model of the disease, we provide evidence that hyperactivity, a typical symptom of FXS, is not wholly induced by the lack of Fmrp in mice but also occurs as a result of its reduced expression in their mother. Genetically wild-type offspring of mutant mothers also had hyperactivity, albeit less pronounced than the mutant offspring. However, other features of FXS reproduced in the mouse model, such as sensory hyperreactivity and seizure susceptibility, were exclusively associated with the absence of Fmrp in the offspring. These data indicate that fmr-1, the gene encoding Fmrp, can be both an offspring genetic and a maternal environmental factor in producing a neurodevelopmental condition.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ashwood P, Nguyen DV, Hessl D, Hagerman RJ, Tassone F (2010) Plasma cytokine profiles in fragile X subjects: is there a role for cytokines in the pathogenesis? Brain Behav Immun 24:898–902
Atladottir HO, Pedersen MG, Thorsen P, Mortensen PB, Deleuran B, Eaton WW, Parner ET (2009) Association of family history of autoimmune diseases and autism spectrum disorders. Pediatrics 124:687–694
Brown V, Jin P, Ceman S, Darnell JC, O'Donnell WT, Tenenbaum SA, Jin X, Feng Y, Wilkinson KD, Keene JD, Darnell RB, Warren ST (2001) Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell 107:477–487
Chen L, Yun SW, Seto J, Liu W, Toth M (2003) The fragile X mental retardation protein binds and regulates a novel class of mRNAs containing U rich target sequences. Neuroscience 120:1005–1017
Consortium TD-BFX (1994) Fmr1 knockout mice: a model to study fragile X mental retardation. Cell 78:23–33
Cory-Slechta DA, Zuch CL, Fox RA (1996) Comparison of the stimulus properties of a pre- vs. a putative postsynaptic dose of quinpirole. Pharmacol Biochem Behav 55:423–432
Cott J, Carlsson A, Engel J, Lindqvist M (1976) Suppression of ethanol-induced locomotor stimulation by GABA-like drugs. Naunyn Schmiedebergs Arch Pharmacol 295:203–209
Croen LA, Grether JK, Yoshida CK, Odouli R, Van de Water J (2005) Maternal autoimmune diseases, asthma and allergies, and childhood autism spectrum disorders: a case-control study. Arch Pediatr Adolesc Med 159:151–157
Dolen G, Osterweil E, Rao BS, Smith GB, Auerbach BD, Chattarji S, Bear MF (2007) Correction of fragile X syndrome in mice. Neuron 56:955–962
Doolin MT, Barbaux S, McDonnell M, Hoess K, Whitehead AS, Mitchell LE (2002) Maternal genetic effects, exerted by genes involved in homocysteine remethylation, influence the risk of spina bifida. Am J Hum Genet 71:1222–1226
Engberg G, Kling-Petersen T, Nissbrandt H (1993) GABAB-receptor activation alters the firing pattern of dopamine neurons in the rat substantia nigra. Synapse 15:229–238
Fatemi SH, Folsom TD (2010) The role of fragile X mental retardation protein in major mental disorders. Neuropharmacology 40:743–750
Fatemi SH, Kneeland RE, Liesch SB, Folsom TD (2010) Fragile X mental retardation protein levels are decreased in major psychiatric disorders. Schizophr Res 124:246–247
Francis D, Diorio J, Liu D, Meaney MJ (1999) Nongenomic transmission across generations of maternal behavior and stress responses in the rat. Science 286:1155–1158
Grace A (2001) Psychostimulant actions on dopamine and limbic system function: relevance to the pathophysiology and treatment of ADHD. In: Solanto MV, Arnsten AFT, Castellanos FX (eds) Stimulant drugs and ADHD: basic and clinical neuroscience. Oxford University Press, New York, pp 134–155
Hagerman RJ, Hall DA, Coffey S, Leehey M, Bourgeois J, Gould J, Zhang L, Seritan A, Berry-Kravis E, Olichney J, Miller JW, Fong AL, Carpenter R, Bodine C, Gane LW, Rainin E, Hagerman H, Hagerman PJ (2008) Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems. Clin Interv Aging 3:251–262
Halmoy A, Johansson S, Winge I, McKinney JA, Knappskog PM, Haavik J (2010) Attention-deficit/hyperactivity disorder symptoms in offspring of mothers with impaired serotonin production. Arch Gen Psychiatry 67:1033–1043
Johnson WG (2003) Teratogenic alleles and neurodevelopmental disorders. Bioessays 25:464–477
Jyonouchi H, Sun S, Le H (2001) Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression. J Neuroimmunol 120:170–179
Kao DI, Aldridge GM, Weiler IJ, Greenough WT (2010) Altered mRNA transport, docking, and protein translation in neurons lacking fragile X mental retardation protein. Proc Natl Acad Sci USA 107:15601–15606
Koob GF, Swerdlow NR (1988) The functional output of the mesolimbic dopamine system. Ann NY Acad Sci 537:216–227
Labouebe G, Lomazzi M, Cruz HG, Creton C, Lujan R, Li M, Yanagawa Y, Obata K, Watanabe M, Wickman K, Boyer SB, Slesinger PA, Luscher C (2007) RGS2 modulates coupling between GABAB receptors and GIRK channels in dopamine neurons of the ventral tegmental area. Nat Neurosci 10:1559–1568
Li Y, Lin L, Jin P (2008) The microRNA pathway and fragile X mental retardation protein. Biochim Biophys Acta 1779:702–705
Madden TE, Johnson SW (1998) Gamma-hydroxybutyrate is a GABAB receptor agonist that increases a potassium conductance in rat ventral tegmental dopamine neurons. J Pharmacol Exp Ther 287:261–265
Maier SF (2003) Bi-directional immune-brain communication: implications for understanding stress, pain, and cognition. Brain Behav Immun 17:69–85
Meaney MJ (2001) Maternal care, gene expression, and the transmission of individual differences in stress reactivity across generations. Annu Rev Neurosci 24:1161–1192
Miyashiro KY, Beckel-Mitchener A, Purk TP, Becker KG, Barret T, Liu L, Carbonetto S, Weiler IJ, Greenough WT, Eberwine J (2003) RNA cargoes associating with FMRP reveal deficits in cellular functioning in Fmr1 null mice. Neuron 37:417–431
Rouse B, Azen C (2004) Effect of high maternal blood phenylalanine on offspring congenital anomalies and developmental outcome at ages 4 and 6 years: the importance of strict dietary control preconception and throughout pregnancy. J Pediatr 144:235–239
Smith SE, Li J, Garbett K, Mirnics K, Patterson PH (2007) Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci 27:10695–10702
Smolders I, De Klippel N, Sarre S, Ebinger G, Michotte Y (1995) Tonic GABA-ergic modulation of striatal dopamine release studied by in vivo microdialysis in the freely moving rat. Eur J Pharmacol 284:83–91
Starke K, Gothert M, Kilbinger H (1989) Modulation of neurotransmitter release by presynaptic autoreceptors. Physiol Rev 69:864–989
Szczypka MS, Kwok K, Brot MD, Marck BT, Matsumoto AM, Donahue BA, Palmiter RD (2001) Dopamine production in the caudate putamen restores feeding in dopamine-deficient mice. Neuron 30:819–828
Tonelli LH, Postolache TT (2005) Tumor necrosis factor alpha, interleukin-1 beta, interleukin-6 and major histocompatibility complex molecules in the normal brain and after peripheral immune challenge. Neurol Res 27:679–684
Usiello A, Baik JH, Rouge-Pont F, Picetti R, Dierich A, LeMeur M, Piazza PV, Borrelli E (2000) Distinct functions of the two isoforms of dopamine D2 receptors. Nature 408:199–203
Weaver IC, Cervoni N, Champagne FA, D'Alessio AC, Sharma S, Seckl JR, Dymov S, Szyf M, Meaney MJ (2004) Epigenetic programming by maternal behavior. Nat Neurosci 7:847–854
Weaver IC, Champagne FA, Brown SE, Dymov S, Sharma S, Meaney MJ, Szyf M (2005) Reversal of maternal programming of stress responses in adult offspring through methyl supplementation: altering epigenetic marking later in life. J Neurosci 25:11045–11054
Weaver IC, Meaney MJ, Szyf M (2006) Maternal care effects on the hippocampal transcriptome and anxiety-mediated behaviors in the offspring that are reversible in adulthood. Proc Natl Acad Sci USA 103:3480–3485
Yun SW, Platholi J, Flaherty MS, Fu W, Kottmann AH, Toth M (2006) Fmrp is required for the establishment of the startle response during the critical period of auditory development. Brain Res 1110:159–165
Zalfa F, Achsel T, Bagni C (2006) mRNPs, polysomes or granules: FMRP in neuronal protein synthesis. Curr Opin Neurobiol 16:265–269
Zupan B, Toth M (2008a) Wild-type male offspring of fmr-1(+/−) mothers exhibit characteristics of the fragile X phenotype. Neuropsychopharmacology 33:2667–2675
Zupan B, Toth M (2008b) Inactivation of the maternal fragile X gene results in sensitization of GABAB receptor function in the offspring. J Pharmacol Exp Ther 327:820–826
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Zupan, B., Toth, M. (2012). Fmr-1 as an Offspring Genetic and a Maternal Environmental Factor in Neurodevelopmental Disease. In: Denman, R. (eds) Modeling Fragile X Syndrome. Results and Problems in Cell Differentiation, vol 54. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-21649-7_13
Download citation
DOI: https://doi.org/10.1007/978-3-642-21649-7_13
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-21648-0
Online ISBN: 978-3-642-21649-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)